A single vial of human insulin costs between $2.28 and $3.42 to manufacture. That’s for a standard 1,000-unit vial, the same product that has historically carried a pharmacy list price of $100 to $300 or more. The gap between production cost and retail price is one of the most scrutinized markups in modern medicine, and understanding where the money actually goes requires looking well beyond the factory floor.
Raw Production Costs
Modern insulin is made by genetically engineered bacteria or yeast cells. A modified version of the human insulin gene is inserted into the host organism’s DNA, which then produces an insulin precursor as it grows in large fermentation tanks. That precursor is harvested, chemically cleaved into active insulin, then purified and refolded into the correct shape. The process is essentially the same whether the end product is older-style human insulin or the newer analog insulins (like glargine or lispro) that most people use today.
The key difference is in raw ingredient costs. The active ingredient in standard human insulin runs about $24,750 per kilogram. For insulin glargine, one of the most commonly prescribed long-acting analogs, that jumps to roughly $68,750 per kilogram. Other analogs can reach $100,000 per kilogram. Those numbers sound large, but a single vial contains only a tiny amount of the active ingredient, which is why the per-vial manufacturing cost stays so low.
Filling and packaging add relatively little. The cost of the glass vial itself, plus the sterile filling process, has been estimated at anywhere from $0.09 to $1.00 per unit depending on the country and production scale. Even at the higher end, total manufacturing cost for a vial of analog insulin lands well under $10.
Why the Price Tag Is So Much Higher
If a vial costs a few dollars to make, the natural question is where the rest of the money goes. A study published in JAMA Health Forum tracked a hypothetical $100 spent on insulin through the U.S. supply chain and found that by 2018, less than half, about $46.73, reached the manufacturer. The rest was absorbed by intermediaries: pharmacies kept $20.42, pharmacy benefit managers (PBMs) took $14.36, and wholesalers captured $8.09. Insurers retained the remaining $10.40.
That distribution changed dramatically over just a few years. In 2014, manufacturers received nearly $70 of every $100 spent, while PBMs, pharmacies, and wholesalers collectively took only about $16.50. By 2018, those intermediaries’ combined share had jumped to $42.90. The system of rebates and fees that PBMs negotiate with manufacturers has been a major driver: manufacturers raise list prices, then pay larger rebates back to PBMs and insurers, inflating the sticker price that uninsured patients and those with high-deductible plans actually face.
Manufacturer Profit Margins
The three companies that dominate global insulin sales, Novo Nordisk, Eli Lilly, and Sanofi, are extraordinarily profitable. Novo Nordisk reported a gross margin of 84.7% in 2024, meaning that for every dollar of revenue, fewer than 16 cents went toward producing the product. That margin covers not just vial-level manufacturing but also quality control, regulatory compliance, cold-chain shipping, and other operational costs. Still, it reflects a business where the gap between production cost and selling price is vast.
Manufacturers argue that research and development expenses justify high prices. Developing a new biosimilar insulin product, even one that copies an existing formula, costs an average of $135 million to $142 million. When failed development programs are factored in, the expected cost per approved product climbs to roughly $200 million. Clinical trials account for the largest share of that spending (about 42%), followed by early pharmacological studies (27%) and patent litigation (12%). These are real costs, but they’re one-time investments spread across years of sales for products with enormous global demand.
What Biosimilars and Price Caps Have Changed
Two recent shifts have started to lower what patients actually pay. First, biosimilar insulins have entered the U.S. market, offering versions of popular analogs at lower list prices. The development pipeline for biosimilars is expensive, but once approved, they increase competition and push prices down.
Second, federal policy has introduced direct price caps for some patients. Under the Inflation Reduction Act, people enrolled in Medicare now pay no more than $35 for a month’s supply of each covered insulin product. That cap took effect in January 2023 for those with Medicare prescription drug plans and was extended to Medicare Part B beneficiaries using insulin pumps. The law also limits total annual out-of-pocket drug spending for Medicare enrollees to $2,000 starting in 2025. Several major manufacturers have voluntarily extended similar $35 caps to their commercially insured and even some uninsured customers, though the breadth and permanence of those programs vary.
These caps change what patients pay at the pharmacy counter, but they don’t change the underlying list prices or the flow of money through the supply chain. The manufacturing cost of insulin remains a few dollars per vial. The hundreds of dollars that have historically appeared on pharmacy receipts reflect a pricing structure built on rebates, intermediary fees, and market concentration rather than the complexity or expense of making the drug itself.